Search Results - TherapeuticArea+%3e+Oncology

566 Results

Sort By:

Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer

Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered...

Published: 9/18/2024 | Inventor(s): Yves Pommier, Lin-kun An, Keli Agama, Evgeny Kiselev, Azhar Ravji

Keywords(s): Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies

Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. Description of Technology: Immunotherapy is...

Published: 9/13/2024 | Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley

Keywords(s):

Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies

Published: 7/26/2024 | Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley

Keywords(s):

Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Development of High-Throughput ELISA Based Binding Assays to Detect p53/p63/p73 Family Protein-DNA Interaction in the 96-well Microplate Format for Drug Screening and Other Clinical and Diagnostic Uses

This technology includes ELISA based binding assays of p53, p63 or p73 provide possibilities to validate genome sequencing results, and allow the performance of more in-depth investigation to address scientific mechanisms, as well as to develop applications for high-throughput clinical and diagnosis usages. While quantitative p53 binding assays have...

Published: 8/12/2024 | Inventor(s): Zhong Chen, Minyoung Jang

Keywords(s):

Category(s): Application > Diagnostics, Application > Research Materials, ResearchProducts > Research Equipment, TherapeuticArea > Oncology

Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma

This technology includes the method of blocking CD38 in expanded natural killer (NK) cell therapy in combination with daratumumab in patients with multiple myeloma. Our in vitro studies have already confirmed the addition of NK cells to myeloma cells that have been exposed to daratumumab enhances myeloma killing compared to single agent treatment. Studies...

Published: 8/12/2024 | Inventor(s): Richard Childs, Jorge Luis Espinoza-Calderon, Maria Berg

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Human Cell Lines, TherapeuticArea > Oncology

Highly Efficient Gene Transfer into Primary and Expanded Human Natural Killer Cells by Lentiviral Transduction for Cancer Therapy

This technology includes an efficient lentiviral vector-based method for gene transfer into NK cells and demonstrates a stable and long-term robust expression of transgenes for the treatment of cancer. High gene transfer rates into primary cells being transduced and the ability to produce high titers of virus particles for large-scale transduction of...

Published: 8/12/2024 | Inventor(s): Richard Childs, Dhanalakshmi (Donna) Chinnasamy

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Oncology

Genetic Manipulation of Natural Killer Cells to Express c-MPL Growth Factor Receptor as a Therapy for Cancer

This technology includes genetic manipulation of natural killer (NK) cells to express thrombopoietin receptor (c-MPL) growth factor receptor as strategy to augment NK cell proliferation and anti-tumor immunity. Many investigational adoptive immunotherapy regimens utilizing NK cells require the administration of IL-2 or IL-15 cytokines to support the...

Published: 8/12/2024 | Inventor(s): David Allan, Richard Childs

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Oncology

Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC).

This technology includes six human monoclonal antibodies (mAbs) that target tumor antigens derived from the CT-RCC HERV-E (human endogenous retrovirus type E) to generate Chimeric Antigen Receptor (CAR) T cells to treat patients with advanced clear cell renal cell carcinoma (ccRCC). These mAbs were identified from Adagene Inc’s human antibody...

Published: 8/12/2024 | Inventor(s): Richard Childs, Long Chen, Elena Cherkasova

Keywords(s):

Category(s): Application > Diagnostics, Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea > Oncology

Epstein-Barr Virus (EBV)-feeder Cell Line

This technology includes irradiated Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL) as feeder cells for the ex vivo expansion of natural killer (NK) cells. EBV-LCL feeder cells, altered by radiation to prevent uncontrolled growth, provide a supportive environment for NK cells to multiply effectively. This method addresses the challenge...

Published: 8/12/2024 | Inventor(s): Richard Childs

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology

Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging

This technology includes 1-13C-ketoglutarate which can be used for imaging the conversion to hydroxyglutarate (HG) or Gln in cancer cells with an IDH1 mutations by hyperpolarized MRI. The ability to detect the status of IDH1 mutations is clinically prognostic for multiple cancers. These exciting observations are limited by two factors, the major one...

Published: 8/12/2024 | Inventor(s): Rolf Swenson, Deepak Sail

Keywords(s):

Category(s): Application > Diagnostics, Application > Software / Apps, Collaboration Sought > Licensing, ResearchProducts > Computational models/software, ResearchProducts > Research Equipment, TherapeuticArea > Oncology

1 2 3 4 5 6 7 8 9 10 ...